Design and application of a new type of biliary-intestinal nutrient tube
10.3760/cma.j.cn121430-20220110-00036
- VernacularTitle:新型胆-肠营养管的设计及应用
- Author:
Jianhua CAO
1
;
Sheng WANG
;
Jianjun YAO
;
Jinlian MA
;
Haiming LI
;
Zhanhu MU
;
Jie CHEN
Author Information
1. 银川市第一人民医院肝胆外科，宁夏银川 750001
- Keywords:
Enteral nutrition;
Enteral nutrition pathway;
Percutaneous transhepatic cholangiography drainage;
Design;
Application
- From:
Chinese Critical Care Medicine
2022;34(7):762-763
- CountryChina
- Language:Chinese
-
Abstract:
The establishment of a nutritional pathway is the premise and basis of nutritional therapy for patients with malignant tumor. The nasogastric tube, nasoenteric tube, and percutaneous endoscopic gastric/jejunostomy are commonly used clinical pathways for enteral nutrition (EN) therapy. However, these EN pathways are often difficult to establish in patients with malignant obstructive jaundice (MOJ) with pyloric or duodenum primary obstruction. For this reason, a new type biliary-intestinal nutrient tube placed through percutaneous transhepatic cholangiography drainage (PTCD) pathway was designed by the medical staff of hepatobiliary surgery department of Yinchuan First People's Hospital, and National Utility Model Patent of China were obtained (ZL 2020 2 0283951.5, ZL 2020 2 0288938.9). The new biliary-intestinal nutrient tube has two types: double-lumen tube and single-lumen tube, which consists of tube head, tube body, tail ring and developing ring. The double lumen tube realizes bile internal drainage and EN simultaneously through the double lumen structure of the tube body. The single-lumen tube is used for nutrient infusion after bile duct metal stent implantation, which is not limited by the type of nutrient solution. The tail ring of the two types of nutrient tube is placed in the upper jejunum to reduce retrograde infection and unexpected extubation. Compared with the prior art, the utility model has the advantages of simple structure, reasonable design, safe and effective placement through PTCD pathway, and opens up a new EN path for MOJ patients.
